Enobia Pharma Inc.

Alexion Pharmaceuticals Inc. has had an impressive eight-year run with Soliris (eculizumab), building its one and only drug into a blockbuster by doggedly identifying new patients around the world

Alexion Pharmaceuticals said it has completed its rolling biologics license application submission to the FDA for asfotase alfa as a treatment for hypophosphatasia (HPP), a chronic and progressive ult

Biotechnology companies ended 2014 with $6bn in new venture capital in their pockets, which was the biggest annual total since 2007, but that's after private startups and early-stage businesses raised

Wall Street was not surprised on 28 May by the US FDA granting Alexion Pharmaceuticals' investigational hypophosphatasia (HPP) drug asfotase alfa (ENB-0040) a breakthrough therapy designation, given t